# US 6,727,246 B2 · 1-(aminoalkyl)-3-sulfonylindole-and-indazole derivatives as 5-hydroxytryptamine-6 ligands

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 6,727,246 B2
- Document ID: US6727246B2
- Status: Granted
- Kind: B2
- Application number: 10/453,009
- Filed: 2003-06-03
- Published: 2003-12-18
- Granted: 2004-04-27
- Earliest claimed: 2002-06-04
- Assignees: Wyeth
- Inventors: Ronald Charles Bernotas; Steven Edward Lenicek; Schuyler A. Antane; Ping Zhou; Yanfang Li
- Web page: https://patentgrep.com/patent/US6727246B2

## CPC

- C07D 209/48: with oxygen atoms in positions 1 and 3, e.g. phthalimide
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/22: Anxiolytics
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C07D 209/08: with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
- C07D 209/30: with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D 231/56: Benzopyrazoles; Hydrogenated benzopyrazoles
- C07D 403/12: linked by a chain containing hetero atoms as chain links
- C07D 409/12: linked by a chain containing hetero atoms as chain links
- C07D 513/04: Ortho-condensed systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides compounds of formula I and the use thereof for the treatment of central nervous system disorders related to or affected by the 5-HT6 receptor.

## Claims

### Claim 1

A compound of formula I
wherein
W is N or CR2;
R is H, halogen, CN, OCO2R7, CO2R8, CONR9R10, SOpR11, NR12R13, OR14, COR15 or a C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C3-C7cycloalkyl, cycloheteroalkyl, aryl or heteroaryl group each optionally substituted;
R1 is an optionally substituted C1-C6alkyl, C3-C7cycloalkyl, aryl, or heteroaryl group or an optionally substituted 8- to 13-membered bicyclic or tricyclic ring system having a N atom at the bridgehead and optionally containing 1, 2 or 3 additional heteroatoms selected from N, O or S;
R2 is H, halogen, or a C1-C6alkyl, C1-C6alkoxy, C3-C7cycloalkyl, aryl or heteroaryl group each optionally substituted;
R3 and R4 are each independently H or an optionally substituted C1-C6alkyl group;
R5 and R6 are each independently H or a C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C3-C7cycloalkyl, cycloheteroalkyl, aryl or heteroaryl group each optionally substituted or R5 and R6 may be taken together with the atom to which they are attached to form an optionally substituted 5- to 8-membered ring optionally containing an additional heteroatom selected from O, NR16 or SOx;
m is 0 or an integer of 1, 2 or 3;
n is an integer of 2, 3, 4 or 5;
p and x are each independently 0 or an integer of 1 or 2;
R7, R8, R11, R15 and R16 are each independently H or a C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C3-C6cycloalkyl, cycloheteroalkyl, aryl or heteroaryl group each optionally substituted;
R9 and R10 are each independently H or a C1-C6alkyl or C3-C7cycloalkyl group each optionally substituted or R9 and R10 may be taken together with the atom to which they are attached to form a 5- to 7-membered ring optionally containing another heteroatom selected from O, NR18 or S;
R12 and R13 are each independently H or an optionally substituted C1-C4alkyl group or R12 and R13 may be taken together with the atom to which they are attached to form a 5- to 7-membered ring optionally containing another heteroatom selected from O, NR17 or SOq;
R14 is a C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C3-C7cycloalkyl, cycloheteroalkyl, aryl or heteroaryl group each optionally substituted;
q is 0 or an integer of 1 or 2; and
R17 and R18 are each independently H or a C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C3-C7cycloalkyl, cycloheteroalkyl, aryl or heteraryl group each optionally substituted; or
a stereoisomer thereof or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

The compound according to claim 1 wherein n is 2.

### Claim 3 (depends on 1)

The compound according to claim 1 wherein R1 is an optionally substituted phenyl, naphthyl or imidazothiazolyl group.

### Claim 4 (depends on 1)

The compound according to claim 1 wherein R2 is H or CH3.

### Claim 5 (depends on 1)

The compound according to claim 1 wherein R5 and R6 are each independently H or C1-C4alkyl.

### Claim 6 (depends on 2)

The compound according to claim 2 wherein R is H, halogen or C1-C4alkoxy.

### Claim 7 (depends on 6)

The compound according to claim 6 wherein R3 and R4 are H.

### Claim 8 (depends on 7)

The compound according to claim 7 wherein R1 is an optionally substituted phenyl, naphthyl or imidazothiazolyl group and R2 is H or CH3.

### Claim 9 (depends on 1)

The compound according to claim 1 selected from the group consisting of:
2-[5-methoxy-3-(phenylsulfonyl)-1H-indol-1-yl]ethylamine;
6-chloro-1-(3-morpholin-4-yl-propyl)-3-(phenylsulfonyl)-1H-indole;
5-methoxy-3-(phenylsulfonyl)-1-(3-pyrrolidin-1-yl-propyl)-1H-indole;
N,N-dimethyl-N-{3-[3-(4-fluorophenylsulfonyl)-5-methoxy-1H-indol-1-yl]-propyl}-amine;
N,N-dibenzyl-N-{[2-(3-phenylsulfonyl)-1H-indol-1-yl]ethyl}amine;
5-methoxy-3-(phenylsulfonyl)-1-(2-pyrrolidin-1-yl-ethyl)-1H-indole;
N,N-dimethyl-N-{2-[3-(4-fluorophenylsulfonyl)-5-methoxy-1H-indol-1-yl]-ethyl}amine;
N,N-dimethyl-3-[3-(phenylsulfonyl)-1H-indol-1-yl]propan-1-amine;
2-[3-(phenylsulfonyl)-1H-indol-1-yl]ethylamine;
2-[3-(naphth-1-ylsulfonyl)-1H-indol-1-yl]ethylamine;
2-{3-[(6-chloro-imidazo[2,1-b][1,3]thiazol-5-yl)lsulfonyl]-1H-indol-1-yl]ethylamine;
3-[3-(phenylsulfonyl)-1H-indol-1-yl]propan-1-amine;
3-[3-(4-fluorophenylsulfonyl)-5-methoxy-1H-indol-1-yl]propan-1-amine;
3-(phenylsulfonyl)-1-(2-piperidin-1-yl-ethyl)-1H-indole;
3-[5-methoxy-3-(phenylsulfonyl)-1H-indol-1-yl]propan-1-amine;
3-[6-chloro-3-(phenylsulfonyl)-1H-indol-1-yl]propan-1-amine;
6-chloro-1-(2-morpholin-4-yl-ethyl)-3-(phenylsulfonyl)-1H-indole;
3-(phenylsulfonyl)-1-(3-piperidin-1-yl-propyl)-1H-indole;
2-[6-chloro-3-(phenylsulfonyl)-1H-indol-1-yl]ethylamine;
2-[3-(4-fluorophenylsulfonyl)-5-methoxy-1H-indol-1-yl]ethylamine;
N,N-dimethyl-N-{2-[2-methyl-3-(phenylsulfonyl)-1H-indol-1-yl]ethyl}amine;
N,N-dimethyl-N-{2-[5-carbonitrile-3-(phenylsulfonyl)-1H-indol-1-yl]ethyl}amine hydrochloride;
N,N-dimethyl-N-{2-[4-fluoro-3-(phenylsulfonyl)-1H-indol-1-yl]ethyl}amine;
N,N-dimethyl-N-{2-[7-chloro-3-(phenylsulfonyl)-1H-indol-1-yl]-ethyl}amine;
N,N-dimethyl-N-{2-[4-chloro-3-(phenylsulfonyl)-1H-indol-1-yl]-ethyl}amine;
N,N-dimethyl-N-{2-[4-methyl-3-(phenylsulfonyl)-1H-indol-1-yl]ethyl}amine;
N,N-dimethyl-N-{2-[7-ethyl-3-(phenylsulfonyl)-1H-indol-1-yl]ethyl}amine;
N,N-dimethyl-{N-[3-(thien-2ylsulfonyl)-1H-indol-1-yl]ethyl}amine;
2-[3-(thien-2-ylsulfonyl)-1H-indol-1-yl]ethylamine;
1-[2-(dimethylamino)ethyl]-3-(phenylsulfonyl)-1H-indole-5-carbonitrile;
1-[2-(dimethylamino)ethyl]-3-(phenylsulfonyl)-1H-indole-7-carbonitrile;
2-[5-methoxy-3-(phenylsulfonyl)-1H-indazol-1-yl)]ethylamine;
6-chloro-1-(3-morpholin-4-yl-propyl)-3-(phenylsulfonyl)-1H-indazole;
5-methoxy-3-(phenylsulfonyl)-1-(3-pyrrolidin-1-yl-propyl)-1H-indazole;
N,N-dimethyl-N-{3-[3-(4-fluorophenylsulfonyl)-5-methoxy-1H-indazol-1-yl]-propyl}-amine;
N,N-dibenzyl-N-{[2-(3-phenylsulfonyl)-1H-indazol-1-yl]ethyl}amine;
5-methoxy-3-(phenylsulfonyl)-1-(2-pyrrolidin-1-yl-ethyl)-1H-indazole;
N,N-dimethyl-N-3-{2-[3-(4-fluorophenylsulfonyl)-5-methoxy-indazol-1-yl]-ethyl}amine;
N,N-dimethyl-N-3-[3-(phenylsulfonyl)-1H-indazol-1-yl]propan-1-amine;
2-[3-(phenylsulfonyl)-1H-indazol-1-yl]ethylamine;
2-[3-(naphth-1-ylsulfonyl)-1H-indazol-1-yl]ethylamine;
2-{3-[(6-chloro-imidazo[2,1-b][1,3]thiazol-5-yl)lsulfonyl]-1H-indazol-1-yl]ethylamine;
3-[3-(phenylsulfonyl)-1H-indazol-1-yl]propan-1-amine;
3-[3-(4-fluorophenysulfonyl)-5-methoxy-indazol-1-yl]propan-1-amine;
3-(phenylsulfonyl)-1-(2-piperidin-1-yl-ethyl)-1H-indazole;
3-[5-methoxy-3-(phenylsulfonyl)-1H-indazol-1-yl]propan-1-amine;
3-[6-chloro-3-(phenylsulfonyl)-1H-indazol-1-yl]propan-1-amine;
6-chloro-1-(2-morpholin-4-yl-ethyl)-3-(phenylsulfonyl)-1H-indazole;
3-(phenylsulfonyl)-1-(3-piperidin-1-yl-propyl)-1H-indazole;
2-[6-chloro-3-(phenylsulfonyl)-1H-indazol-1-yl]ethylamine;
2-[3-(4-fluorophenylsulfonyl)-5-methoxy-1H-indazol-1-yl]ethylamine;
N,N-dimethyl-N-{2-[2-methyl-3-(phenylsulfonyl)-1H-indazol-1-yl]ethyl}-amine;
N,N-dimethyl-N-{2-[2-methyl-3-(naphth-1-ylsulfonyl)-1H-indazol-1-yl]ethyl}-amine;
N,N-dimethyl-N-{2-[5-carbonitrile-3-(phenylsulfonyl)-1H-indazol-1-yl]ethyl}amine;
N,N-dimethyl-N-{2-[4-fluoro-3-(phenylsulfonyl)-1H-indazol-1-yl]ethyl}amine;
N,N-dimethyl-N-{2-[3-(naphth-1ylsulfonyl)-1H-indazol-1-yl]ethyl}amine;
N,N-dimethyl-N-{2-{[3-(6-chloro-imidazo[1,2-b][1,3]thiazol-5-yl)sulfonyl]-1H-indazol-1-yl}ethyl}amine;
N,N-dimethyl-N-{2-[7-chloro-3-(phenylsulfonyl)-1H-indazol-1-yl]-ethyl}amine;
N,N-dimethyl-N-{2-[4-chloro-3-(phenylsulfonyl)-1H-indazol-1-yl]-ethyl}amine;
N,N-dimethyl-N-{2-[4-methyl-3-(phenylsulfonyl)-1H-indazol-1-yl]ethyl}-amine;
the stereoisomers thereof; and
the pharmaceutically acceptable salts thereof.

### Claim 10

A method for the treatment of a disorder of the central nervous system related to or affected by the 5-HT6 receptor in a patient in need thereof which comprises providing to said patient a therapeutically effective amount of a compound of formula I
wherein
W is N or CR2;
R is H, halogen, CN, OCO2R7, CO2R8, CONR9R10, SOpR11, NR12R13, OR14, COR15 or a C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C3-C7cycloalkyl, cycloheteroalkyl, aryl or heteroaryl group each optionally substituted;
R1 is an optionally substituted C1-C6alkyl, C3-C7cycloalkyl, aryl, or heteroaryl group or an optionally substituted 8- to 13-membered bicyclic or tricyclic ring system having a N atom at the bridgehead and optionally containing 1, 2 or 3 additional heteroatoms selected from N, O or S;
R2 is H, halogen, or a C1-C6alkyl, C1-C6alkoxy, C3-C7cycloalkyl, aryl or heteroaryl group each optionally substituted;
R3 and R4 are each independently H or an optionally substituted C1-C6alkyl group;
R5 and R6 are each independently H or a C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C3-C7cycloalkyl, cycloheteroalkyl, aryl or heteroaryl group each optionally substituted or R5 and R6 may be taken together with the atom to which they are attached to form an optionally substituted 5- to 8-membered ring optionally containing an additional heteroatom selected from O, NR16 or SOx;
m is 0 or an integer of 1, 2 or 3;
n is an integer of 2, 3, 4 or 5;
p and x are each independently 0 or an integer of 1 or 2;
R7, R8, R11, R15 and R16 are each independently H or a C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C3-C6cycloalkyl, cycloheteroalkyl, aryl or heteroaryl group each optionally substituted;
R9 and R10 are each independently H or a C1-C6alkyl or C3-C7cycloalkyl group each optionally substituted or R9 and R10 may be taken together with the atom to which they are attached to form a 5- to 7-membered ring optionally containing another heteroatom selected from O, NR18 or S;
R12 and R13 are each independently H or an optionally substituted C1-C4alkyl group or R12 and R13 may be taken together with the atom to which they are attached to form a 5- to 7-membered ring optionally containing another heteroatom selected from O, NR17 or SOq;
R14 is a C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C3-C7cycloalkyl, cycloheteroalkyl, aryl or heteroaryl group each optionally substituted;
q is 0 or an integer of 1 or 2; and
R17 and R18 are each independently H or a C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C3-C7cycloalkyl, cycloheteroalkyl, aryl or heteraryl group each optionally substituted; or
the stereoisomers thereof or the pharmaceutically acceptable salts thereof.

### Claim 11 (depends on 10)

The method according to claim 10 wherein said disorder is an anxiety disorder or a cognitive disorder.

### Claim 12 (depends on 10)

The method according to claim 10 wherein said disorder is a neurodegenerative disorder.

### Claim 13 (depends on 11)

The method according to claim 11 wherein said disorder is attention deficit disorder or obsessive compulsive disorder.

### Claim 14 (depends on 12)

The method according to claim 12 wherein said disorder is stroke or head trauma.

### Claim 15

A pharmaceutical composition which comprises a pharmaceutically acceptable carrier and an effective amount of a compound of formula I
wherein
W is N or CR2;
R is H, halogen, CN, OCO2R7, CO2R8, CONR9R10, SOpR11, NR12R13, OR14, COR15 or a C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C3-C7cycloalkyl, cycloheteroalkyl, aryl or heteroaryl group each optionally substituted;
R1 is an optionally substituted C1-C6alkyl, C3-C7cycloalkyl, aryl, or heteroaryl group or an optionally substituted 8- to 13-membered bicyclic or tricyclic ring system having a N atom at the bridgehead and optionally containing 1, 2 or 3 additional heteroatoms selected from N, O or S;
R2 is H, halogen, or a C1-C6alkyl, C1-C6alkoxy, C3-C7cycloalkyl, aryl or heteroaryl group each optionally substituted;
R3 and R4 are each independently H or an optionally substituted C1-C6alkyl group;
R5 and R6 are each independently H or a C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C3-C7cycloalkyl, cycloheteroalkyl, aryl or heteroaryl group each optionally substituted or R5 and R6 may be taken together with the atom to which they are attached to form an optionally substituted 5- to 8-membered ring optionally containing an additional heteroatom selected from O, NR16 or SOx;
m is 0 or an integer of 1, 2 or 3;
n is an integer of 2, 3, 4 or 5;
p and x are each independently 0 or an integer of 1 or 2;
R7, R8, R11, R15 and R16 are each independently H or a C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C3-C6cycloalkyl, cycloheteroalkyl, aryl or heteroaryl group each optionally substituted;
R9 and R10 are each independently H or a C1-C6alkyl or C3-C7cycloalkyl group each optionally substituted or R9 and R10 may be taken together with the atom to which they are attached to form a 5- to 7-membered ring optionally containing another heteroatom selected from O, NR18 or S;
R12 and R13 are each independently H or an optionally substituted C1-C4alkyl group or R12 and R13 may be taken together with the atom to which they are attached to form a 5- to 7-membered ring optionally containing another heteroatom selected from O, NR17 or SOq;
R14 is a C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C3-C7cycloalkyl, cycloheteroalkyl, aryl or heteroaryl group each optionally substituted;
q is 0 or an integer of 1 or 2; and
R17 and R18 are each independently H or a C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C3-C7cycloalkyl, cycloheteroalkyl, aryl or heteraryl group each optionally substituted; or
the stereoisomers thereof or the pharmaceutically acceptable salts thereof.

### Claim 16 (depends on 15)

The composition according to claim 15 having the formula I compound wherein n is 2.

### Claim 17 (depends on 16)

The composition according to claim 16 having the formula I compound wherein R1 is an optionally substituted phenyl, naphthyl or imidazothiazolyl group.

### Claim 18 (depends on 17)

The composition according to claim 17 wherein R is H, halogen or C1-C4alkoxy; R2 is H or CH3, R3 and R4 are H; and R5 and R6 are each independently H or C1-C4alkyl.

### Claim 19 (depends on 15)

The composition according to claim 15 having the formula I compound selected from the group consisting of:
2-[5-methoxy-3-(phenylsulfonyl)-1H-indol-1-yl]ethylamine;
6-chloro-1-(3-morpholin-4-yl-propyl)-3-(phenylsulfonyl)-1H-indole;
5-methoxy-3-(phenylsulfonyl)-1-(3-pyrrolidin-1-yl-propyl)-1H-indole;
N,N-dimethyl-N-{3-[3-(4-fluorophenylsulfonyl)-5-methoxy-1H-indol-1-yl]-propyl}-amine;
N,N-dibenzyl-N-{[2-(3-phenylsulfonyl)-1H-indol-1-yl]ethyl}amine;
5-methoxy-3-(phenylsulfonyl)-1-(2-pyrrolidin-1-yl-ethyl)-1H-indole;
N,N-dimethyl-N-{2-[3-(4-fluorophenylsulfonyl)-5-methoxy-1H-indol-1-yl]-ethyl}amine;
N,N-dimethyl-3-[3-(phenylsulfonyl)-1H-indol-1-yl]propan-1-amine;
2-[3-(phenylsulfonyl)-1H-indol-1-yl]ethylamine;
2-[3-(naphth-1-ylsulfonyl)-1H-indol-1-yl]ethylamine;
2-{3-[(6-chloro-imidazo[2,1-b][1,3]thiazol-5-yl)lsulfonyl]-1H-indol-1-yl]ethyl}amine;
3-[3-(phenylsulfonyl)-1H-indol-1-yl]propan-1-amine;
3-[3-(4-fluorophenylsulfonyl)-5-methoxy-1H-indol-1-yl]propan-1-amine;
3-(phenylsulfonyl)-1-(2-piperidin-1-yl-ethyl)-1H-indole;
3-[5-methoxy-3-(phenylsulfonyl)-1H-indol-1-yl]propan-1-amine;
3-[6-chloro-3-(phenylsulfonyl)-1H-indol-1-yl]propan-1-amine;
6-chloro-1-(2-morpholin-4-yl-ethyl)-3-(phenylsulfonyl)-1H-indole;
3-(phenylsulfonyl)-1-(3-piperidin-1-yl-propyl)-1H-indole;
2-[6-chloro-3-(phenylsulfonyl)-1H-indol-1-yl]ethylamine;
2-[3-(4-fluorophenylsulfonyl)-5-methoxy-1H-indol-1-yl]ethylamine;
N,N-dimethyl-N-{2-[2-methyl-3-(phenylsulfonyl)-1H-indol-1-yl]ethyl}amine;
N,N-dimethyl-N-{2-[5-carbonitrile-3-(phenylsulfonyl)-1H-indol-1-yl]ethyl}amine hydrochloride;
N,N-dimethyl-N-{2-[4-fluoro-3-(phenylsulfonyl)-1H-indol-1-yl]ethyl}amine;
N,N-dimethyl-N-{2-[7-chloro-3-(phenylsulfonyl)-1H-indol-1-yl]-ethyl}amine;
N,N-dimethyl-N-{2-[4-chloro-3-(phenylsulfonyl)-1H-indol-1-yl]-ethyl}amine;
N,N-dimethyl-N-{2-[4-methyl-3-(phenylsulfonyl)-1H-indol-1-yl]ethyl}amine;
N,N-dimethyl-N-{2-[7-ethyl-3-(phenylsulfonyl)-1H-indol-1-yl]ethyl}amine;
N,N-dimethyl-{N-[3-(thien-2ylsulfonyl)-1H-indol-1-yl]ethyl}amine;
2-[3-(thien-2-ylsulfonyl)-1H-indol-1-yl]ethylamine;
1-[2-(dimethylamino)ethyl]-3-(phenylsulfonyl)-1H-indole-5-carbonitrile;
1-[2-(dimethylamino)ethyl]-3-(phenylsulfonyl)-1H-indole-7-carbonitrile;
2-[5-methoxy-3-(phenylsulfonyl)-1H-indazol-1-yl)]ethylamine;
6-chloro-1-(3-morpholin-4-yl-propyl)-3-(phenylsulfonyl)-1H-indazole;
5-methoxy-3-(phenylsulfonyl)-1-(3-pyrrolidin-1-yl-propyl)-1H-indazole;
N,N-dimethyl-N-{3-[3-(4-fluorophenylsulfonyl)-5-methoxy-1H-indazol-1-yl]-propyl}-amine;
N,N-dibenzyl-N-([2-(3-phenylsulfonyl)-1H-indazol-1-yl]ethyl}amine;
5-methoxy-3-(phenylsulfonyl)-1-(2-pyrrolidin-1-yl-ethyl)-1H-indazole;
N,N-dimethyl-N-3-{2-[3-(4-fluorophenylsulfonyl)-5-methoxy-indazol-1-yl]-ethyl}amine;
N,N-dimethyl-N-3-[3-(phenylsulfonyl)-1H-indazol-1-yl]propan-1-amine;
2-[3-(phenylsulfonyl)-1H-indazol-1-yl]ethylamine;
2-[3-(naphth-1-ylsulfonyl)-1H-indazol-1-yl]ethylamine;
2-{3-[(6-chloro-imidazo[2, 1-b][1,3]thiazol-5-yl)lsulfonyl]-1H-indazol-1-yl]ethylamine;
3-[3-(phenylsulfonyl)-1H-indazol-1-yl]propan-1-amine;
3-[3-(4-fluorophenylsulfonyl)-5-methoxy-indazol-1-yl]propan-1-amine;
3-(phenylsulfonyl)-1-(2-piperidin-1-yl-ethyl)-1H-indazole;
3-[5-methoxy-3-(phenylsulfonyl)-1H-indazol-1-yl]propan-1-amine;
3-[6-chloro-3-(phenylsulfonyl)-1H-indazol-1-yl]propan-1-amine;
6-chloro-1-(2-morpholin-4-yl-ethyl)-3-(phenylsulfonyl)-1H-indazole;
3-(phenylsulfonyl)-1-(3-piperidin-1-yl-propyl)-1H-indazole;
2-[6-chloro-3-(phenylsulfonyl)-1H-indazol-1-yl]ethylamine;
2-[3-(4-fluorophenylsulfonyl)-5-methoxy-1H-indazol-1-yl]ethylamine;
N,N-dimethyl-N-{2-[2-methyl-3-(phenylsulfonyl)-1H-indazol-1-yl]ethyl}-amine;
N,N-dimethyl-N-{2-[2-methyl-3-(naphth-1-ylsulfonyl)-1H-indazol-1-yl]ethyl}-amine;
N,N-dimethyl-N-{2-[5-carbonitrile-3-(phenylsulfonyl)-1H-indazol-1-yl]ethyl}amine;
N,N-dimethyl-N-{2-[4-fluoro-3-(phenylsulfonyl)-1H-indazol-1-yl]ethyl}amine;
N,N-dimethyl-N-{2-[3-(naphth-1-ylsulfonyl)-1H-indazol-1-yl]ethyl}amine;
N,N-dimethyl-N-(2-{[3-(6-chloro-imidazo[1,2-b][1,3]thiazol-5-yl)sulfonyl]-1H-indazol-1-yl}ethyl}amine;
N,N-dimethyl-N-{2-[7-chloro-3-(phenylsulfonyl)-1H-indazol-1-yl]-ethyl}amine;
N,N-dimethyl-N-{2-[4-chloro-3-(phenylsulfonyl)-1H-indazol-1-yl]-ethyl}amine;
N,N-dimethyl-N-{2-[4-methyl-3-(phenylsulfonyl)-1H-indazol-1-yl]ethyl}-amine;
the stereoisomers thereof; and
the pharmaceutically acceptable salts thereof.

### Claim 20

A process for the preparation of a compound of formula I
wherein
W is N or CR2;
R is H, halogen, CN, OCO2R7, CO2R8, CONR9R10, SOpR11, NR12R13, OR14, COR15 or a C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C3-C7cycloalkyl, cycloheteroalkyl, aryl or heteroaryl group each optionally substituted;
R1 is an optionally substituted C1-C6alkyl, C3-C7cycloalkyl, aryl, or heteroaryl group or an optionally substituted 8- to 13-membered bicyclic or tricyclic ring system having a N atom at the bridgehead and optionally containing 1, 2 or 3 additional heteroatoms selected from N, O or S;
R2 is H, halogen, or a C1-C6alkyl, C1-C6alkoxy, C3-C7cycloalkyl, aryl or heteroaryl group each optionally substituted;
R3 and R4 are each independently H or an optionally substituted C1-C6alkyl group;
R5 and R6 are each independently H or a C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C3-C7cycloalkyl, cycloheteroalkyl, aryl or heteroaryl group each optionally substituted or R5 and R6 may be taken together with the atom to which they are attached to form an optionally substituted 5- to 8-membered ring optionally containing an additional heteroatom selected from O, NR16 or SOx;
m is 0 or an integer of 1, 2 or 3;
n is an integer of 2, 3, 4 or 5;
p and x are each independently 0 or an integer of 1 or 2;
R7, R8, R11, R15 and R16 are each independently H or a C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C3-C6cycloalkyl, cycloheteroalkyl, aryl or heteroaryl group each optionally substituted;
R9 and R10 are each independently H or a C1-C6alkyl or C3-C7cycloalkyl group each optionally substituted or R9 and R10 may be taken together with the atom to which they are attached to form a 5- to 7-membered ring optionally containing another heteroatom selected from O, NR18 or S;
R12 and R13 are each independently H or an optionally substituted C1-C4alkyl group or R12 and R13 may be taken together with the atom to which they are attached to form a 5- to 7-membered ring optionally containing another heteroatom selected from O, NR17 or SOq;
R14 is a C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C3-C7cycloalkyl, cycloheteroalkyl, aryl or heteroaryl group each optionally substituted;
q is 0 or an integer of 1 or 2; and
R17 and R18 are each independently H or a C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C3-C7cycloalkyl, cycloheteroalkyl, aryl or heteraryl group each optionally substituted; or
which process comprises reacting a compound of formula II
wherein W, R, R1 and m are as defined hereinabove with a haloalkylamine of formula III
wherein Hal is Cl, Br or I and R3, R4, R5, R6 and n are as defined hereinabove in the presence of a base optionally in the presence of a solvent.
